Jorge Kalil is Professor of Clinical Immunology and Allergy and Director of the Laboratory of Immunology at the Heart Institute (InCor), School of Medicine, University of São Paulo (FMUSP), Brazil. He is Adjunct Professor at the George Washington University, DC, USA, and at the Case Westen University, Cleveland. He represents Latin America in the scientific advisory board of the International Institute of Genetic Engineering and Biotechnology (ICGEB), an UNO Institution since 2013 and a member of the Brazilian Academy of Sciences since 1995. Since 2001, he coordinates iii-Institute for Investigative Immunology, a National Institute linked to the Ministry of Science and Technology, in Brazil. In addition, he co-chairs the Federation of Clinical Immunology Societies - FOCIS Center of Excellence in São Paulo and member of the Council of the USP Pasteur Institute’s board since 2018. He is member of the DSMB/NIH for analyses of phase 3 clinical trials of vaccines anti COVID supported by the US government and board member of COVAX, a WHO/GAVI/CEPI initiative to selecting and buying COVID vaccines to distribute to the world. Kalil graduated in Medicine in Brazil (1977), has a Master’s degree in Immunology and Immunogenetics and is Doctor of Science in Human Biology. He is currently developing vaccines against COVID-19 Streptococcus, HIV, Dengue and Zika in advanced scientific stage.